September 20, 2016
Cambridge, MA

The First Therapy for Duchenne Muscular Dystrophy

Solid Biosciences congratulates Sarepta on the U.S. approval of EXONDYS 51™ (eteplirsen), the first therapy for Duchenne muscular dystrophy. It would not have been possible without the tireless work and commitment of the team at Sarepta, the patient community, the FDA and all those driven to make an approved therapy a reality.

We at Solid hope this event marks the first of many approvals for future therapies that will benefit all patients with this devastating disease. Our mission is to discover and develop treatments that address the full spectrum of Duchenne muscular dystrophy – from its underlying cause to the secondary disorders that result from the disease.

Related news


Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. 


New data from the SGT-001 preclinical program was published today in Molecular Therapy – Methods and Clinical Development

  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.


Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.


As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.


Solid Biosciences Community Update Q2 2016


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


More information about Solid?

Please subscribe to receive our latest news